Surgical management in advanced stages of retinopathy of prematurity; our experience

Retinopathy of prematurity is a potentially blinding condition. In this article we describe the surgical management for advanced stages of the disease [stages 4 and 5]. Indications, options and alternative techniques are described through a review of articles and our personal experience

Intravitreal bevacizumab versus combined bevacizumab and triamcinolone acetonide for neovascular age-related macular degeneration

To compare the short-term outcomes of intravitreal bevacizumab [IVB] with the combination of IVB and intravitreal triamcinolone acetonide [IVB/IVT] for treatment of neovascular age-related macular degeneration [AMD]. This randomized clinical trial was performed on 92 eyes of 90 patients with subfoveal and juxtafoveal choroidal neovascularization [CNV] secondary to AMD. The eyes were randomly assigned to receive IVB 1.25 mg alone [53 eyes] or in combination with IVT 2 mg [39 eyes]. Best-corrected visual acuity [BCVA] and fundus autofluorescence were assessed, and fluorescein angiography [FA] and optical coherence tomography [OCT] were performed at baseline and repeated 6 weeks after treatment. Mean age was 70.6 +/- 8.7 [range 50-89] years and 57.7% of the patients were male. BCVA improved from 1.03 +/- 0.40 to 0.93 +/- 0.38 logMAR [P=0.001] in the IVB group and from 1.08 +/- 0.33 to 0.91 +/- 0.38 logMAR [P=0.008] in the IVB/IVT group. There was a trend toward greater visual improvement with combined therapy [P=0.06]. BCVA improvement was greater in eyes with +1 versus those with +2 [P=0.049] and +3 [P < 0.001] fundus autofluorescence at baseline. Mean decrease in central macular thickness was 113 +/- 115 micro m [P < 0.001] in the IVB group versus 53.96 +/- 125 micro m [P=0.008] in the IVB/IVT group with no intergroup difference [P=0.38]. FA showed decreased leakage in 57.4%, increased leakage in 12.8% and no change in 29.8% of patients in the IVB group. Corresponding figures were 60.0%, 5.7% and 34.3% in the IVB/IVT group [P=0.556]. Addition of triamcinolone acetonide to bevacizumab for treatment of neovascular AMD does not seem to significantly increase its short-term efficacy. More severe fundus autofluorescence appears to be predictive of poorer response to treatment

Efficacy of memantine in acute non-arteritic ischemic optic neuropathy

Evaluation of efficacy of Memantine [N-Methyl-D-Aspartate Receptor Antagonist] on visual function of patients with acute non-arteritic ischemic optic neuropathy [NAION]. The study was conducted as interventional case series from November 2005 through November 2006 in Farabi Eye Hospital. Twenty-two patients with acute NAION of less than 8 weeks duration entered the study. Memantine was prescribed with a dose of 5 mg per day for the first week and 10 mg per day for the following two weeks. Baseline best corrected visual acuity [BCVA]; visual evoked potential [VEP] and visual field was done for all patients. BCVA recording repeated 3 weeks, 3 and 6 months later. VEP and perimetry repeated 3 months after treatment. After 3 weeks, 3 and 6 months, BCVA improved -0.32 +/- 0.40 LogMAR, -0.51 +/- 0.49 and -0.51 +/- 0.49, respectively [P=0.005, P=0.001 and P=0.001, respectively]. VEP recordings after 3 months, demonstrated -8.61 +/- 14.51 db mean decrease in implicit time [P=0.019]. Amplitude of voltage did not show significant difference with baseline [P=0.10]. Perimetry results after 3 months showed that mean deviation [MD] improved 2.77 +/- 3.94 db [P=0.016]. Memantine resulted in significant improvement of BCVA 3 weeks, 3 and 6 months after treatment of acute NAION. Memantine also resulted in significant decrease of implicit time and significant improvement of mean deviation in VEP and perimetry after 3 months

Epidemiology of ocular trauma in Tehran, Iran: A retrospective survey of 959 cases / 国际眼科杂志(Guoji Yanke Zazhi)

AIM: To review the characteristics, complications, and epidemiology of perforating eye injury treated at a referral eye centre in Tehran, over one year, ·METHODS: The medical records of 959 patients hospitalized in Farabi Eye Hospital, Tehran, Iran, due to ocular trauma in 2002 were studied. Information recorded included demographic information (age, sex, and occupation), offending agent, type of trauma, initial visual acuity, location where trauma occurred, accompanying signs and symptoms, and types of treatment provided. ·RESULTS: Mean age of patients was (22.6±16.4) years with a peak age of 21-25 years in males and under 5 years in females. The ratio of male to female was 4.2:1.62.4% of patients had penetrating trauma, 33.9% had blunt trauma, and 3.7% had mixed or chemical trauma. Metallic agents were the most common cause of penetrating ocular trauma, while stone was the most common blunt counterpart. Foreign bodies were observed in 23.4% of cases. Cornea was the most com-mon site of rupture (46.7%). ·CONCLUSION: Based on this study, penetrating trauma is more common than blunt trauma. Younger individuals are more prone to ocular trauma. Cornea is the most common site of injury.